| Rank | Term | Count | Symbol | P value |
| 1 | hsa04110:Cell cycle | 13 | YWHAZ, CREBBP, TP53, PRKDC, RB1, CDK2, HDAC2, EP300, HDAC1, PCNA, MDM2, MYC, andCUL1 | 1.50E − 14 | 2 | hsa05200:Pathways in cancer | 11 | TRAF2, EP300, HDAC2, HDAC1, CREBBP, TP53, MDM2, RB1, MYC, CDK2, and CTNNB1 | 3.51E − 07 | 3 | hsa05215:Prostate cancer | 7 | EP300, CREBBP, TP53, MDM2, RB1, CDK2, and CTNNB1 | 1.45E − 06 | 4 | hsa05220:Chronic myeloid leukemia | 6 | HDAC2, HDAC1, TP53, MDM2, RB1, and MYC | 1.32E − 05 | 5 | hsa04310:Wnt signaling pathway | 6 | EP300, CREBBP, TP53, MYC, CUL1, and CTNNB1 | 3.78E − 04 | 6 | hsa05222:Small cell lung cancer | 5 | TRAF2, TP53, RB1, MYC, and CDK2 | 4.04E − 04 | 7 | hsa05219:Bladder cancer | 4 | TP53, MDM2, RB1, and MYC | 7.24E − 04 | 8 | hsa04330:Notch signaling pathway | 4 | EP300, HDAC2, HDAC1, and CREBBP | 0.001008 | 9 | hsa04520:Adherens junction | 4 | EP300, CREBBP, SRC, and CTNNB1 | 0.00418 | 10 | hsa04350:TGF-beta signaling pathway | 4 | EP300, CREBBP, MYC, and CUL1 | 0.005889 | 11 | hsa05016:Huntington's disease | 5 | EP300, HDAC2, HDAC1, CREBBP, and TP53 | 0.006736 | 12 | hsa05216:Thyroid cancer | 3 | TP53, MYC, and CTNNB1 | 0.00676 | 13 | hsa04120:Ubiquitin mediated proteolysis | 4 | CUL3, MDM2, BRCA1, and CUL1 | 0.020254 | 14 | hsa05213:Endometrial cancer | 3 | TP53, MYC, and CTNNB1 | 0.020793 | 15 | hsa05214:Glioma | 3 | TP53, MDM2, and RB1 | 0.029762 | 16 | hsa04115:p53 signaling pathway | 3 | TP53, MDM2, and CDK2 | 0.034267 | 17 | hsa05218:Melanoma | 3 | TP53, MDM2, and RB1 | 0.037091 | 18 | hsa05210:Colorectal cancer | 3 | TP53, MYC, and CTNNB1 | 0.050311 | 19 | hsa04210:Apoptosis | 3 | TRAF2, IRAK1, and TP53 | 0.053574 | 20 | hsa03450:Non-homologous end-joining | 2 | XRCC6and PRKDC | 0.05487 | 21 | hsa04916:Melanogenesis | 3 | EP300, CREBBP, and CTNNB1 | 0.067353 | 22 | hsa04114:Oocyte meiosis | 3 | YWHAZ, CDK2, and CUL1 | 0.080913 | 23 | hsa04722:Neurotrophin signaling pathway | 3 | IRAK1, YWHAZ, and TP53 | 0.099295 |
|
|